Iridex CORP

Iridex Corporation received a notification from Nasdaq for failing to meet the minimum $1.00 bid price requirement, triggering a 180-day period to regain compliance.

Iridex Corporation reconvened its Annual Meeting on July 10, 2026, addressing director elections, auditor ratification, and executive compensation, while also detailing a significant governance dispute involving a director and a major shareholder.

IRIDEX Corporation has adjourned its 2026 annual meeting of stockholders to July 10, 2026, with no changes to the proposals for voting.

Iridex Corporation announced its first quarter 2026 financial results, reporting $11.8 million in revenue and reaffirming its full-year 2026 guidance.

Iridex Corporation announced strong fourth quarter and full year 2025 financial results, driven by revenue growth and significant operating expense reductions.

IRIDEX Corporation has entered into a new 90-month triple net lease for approximately 30,784 square feet of office, R&D, and manufacturing space in San Jose, California, with an anticipated July 1, 2026 commencement.

IRIDEX Corporation's Q2 2026 Form 10-Q filing reveals a 7.4% decrease in quarterly revenue and a widening net loss, alongside persistent macroeconomic challenges and internal governance tensions.

IRIDEX Corporation's Q1 2026 results show a marginal decrease in total revenues to $11.8 million, with a net loss of $0.5 million, impacted by a decline in retina product sales.

IRIDEX Corporation announced increased revenues and a narrower operating loss for the third quarter and first nine months of fiscal year 2025, driven by product sales and cost-saving measures.

IRIDEX Corporation reported a significant reduction in net loss and improved cash position for the six months ended June 28, 2025, driven by cost savings and new capital raises, despite a slight decline in gross margin.

IRIDEX Corporation's Q1 2025 results show a slight revenue increase and a significant reduction in operating expenses, alongside a $6 million investment through Series B Preferred Stock.

Iridex Corp's Q3 2024 results show a revenue decrease of 9.9% compared to the same period last year, impacted by softer demand and lower royalties.

IRIDEX Corporation's 2024 10-K filing reveals a decrease in revenue and a net loss, while highlighting strategic partnerships, regulatory adaptations, and macroeconomic challenges.

Iridex Corporation's 2023 annual report reveals a decrease in revenue and an increased net loss compared to the previous year, influenced by macroeconomic conditions.

Romeo R Dizon, Chief Financial Officer of Iridex Corp, purchased 7,900 shares of common stock on September 16, 2026 for $0.63 per share.

Romeo R Dizon, Chief Financial Officer of Iridex Corp, purchased 2,354 shares of common stock on September 14, 2026 for $0.65 per share.

Romeo R Dizon, Chief Financial Officer of Iridex Corp, purchased 5,100 shares of common stock on September 10, 2026 for $0.68 per share.

Romeo R Dizon, Chief Financial Officer of Iridex Corp, purchased 6,668 shares of common stock on August 24, 2026.

Patrick Mercer, President and CEO and a Director of Iridex Corp, reported multiple transactions in common stock on July 10, 2026.

Romeo R Dizon, Chief Financial Officer of Iridex Corp, reported multiple transactions in common stock on July 10, 2026.

IRIDEX Corporation has issued its proxy statement for the 2026 Annual Meeting of Stockholders to be held on June 12, 2026.

IRIDEX Corporation has issued a proxy supplement revising its proposed charter amendments, reducing the authorized common stock increase and retaining stockholder written consent rights, in response to an International Shareholder Services Inc. (ISS) recommendation and broader shareholder feedback.

IRIDEX Corporation received a notification from Nasdaq regarding non-compliance with the minimum stockholders' equity requirement for continued listing.

IRIDEX Corporation is seeking stockholder approval to amend and restate its charter to modernize it, increase authorized common stock, and revise terms related to its Series B Preferred Stock.

Iridex Corporation will hold its annual stockholder meeting on June 11, 2025, to vote on director elections, auditor ratification, share issuance approval, charter amendments, equity incentive plan changes, executive compensation, and meeting adjournment.

Iridex Corporation is holding its annual meeting on June 11, 2025, seeking stockholder approval for several proposals, including director elections, auditor ratification, stock issuance, charter amendments, and executive compensation.

A group including Novel Inspiration International Co., Ltd., Xinpo Venture Capital Co., Ltd., and Shih-Yao David Lin has disclosed a combined beneficial ownership of 29.92% of IRIDEX Corp's common stock, signaling active investment and potential strategic engagement.

Novel Inspiration International Co., Ltd. and Shih-Yao David Lin have significantly increased their stake in IRIDEX Corporation to 24.1% and plan to engage with management on strategic direction and board representation.